Vilazodone for the Treatment of Posttraumatic Stress Disorder

Exclusion Criteria

• •Patients with a concurrent DSM-IV Axis I diagnosis in any of the following categories:
• •1. Delirium, Dementia, Amnestic and other Cognitive disorders
• •2. Lifetime Schizophrenia and other Psychotic Disorders
• •3. lifetime Bipolar I Disorder
• •4. Bipolar-II Disorder with an episode of hypomania within the last year
• •5. Alcohol or Substance Dependence or Abuse (excluding nicotine) in one month prior to the Screening Visit
• •6. Any other concurrent Axis I Disorder (including Major Depressive Disorder) must be secondary to the primary diagnosis of PTSD.
• •Decisional incapacity (dementia)
• •Use of centrally acting medications that potentially have an effect on biological expression
• •Chronic pain levels requiring use of any opiate medications
• •Known exposure to chemicals of physical traumas that cause neuropsychiatric sequelae
• •Past chronic PTSD
• •History of 2 or more treatment failures on SSRIs given primarily for the treatment of PTSD, in adequate does at the Investigator's opinion, for at least 8 weeks
• •History of intolerance or hypersensitivity to SSRI's
• •History of seizures
• •Significant risk of committing suicide, or are homicidal or violent and in the Investigator's opinion in significant imminent risk of hurting others
• •Treated with depot-neuroleptic within 3 months or MAO inhibitors within 30 day prior to Baseline visit
• •Received ECT within 3 months prior to Screening visit
• •Pregnant or nursing, women of childbearing potential who are sexually active and do not use adequate contraception, or who are judged to be unreliable in their use of contraception
• •Positive urine drug screen, unless proven to be prescribed for a short-term course of treatment. Drug screen must be repeated at least 7 days after the last dose of prescription medication containing narcotics
• •A medical condition, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial
• •Requiring concomitant treatment with any psychotropic drug (except zolpidem for sleep)
• •Plans to initiate or terminate any form of psychotherapy or behavior therapy during the study
• •Receiving disability payments (\> 50 % service connections or total Social Security) or who are involved in litigation for PTSD or other psychiatric illnesses.
• •Unable to speak, read, and understand English or are judged by the investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits